Last reviewed · How we verify
SSKI
SSKI, marketed by the Pediatric Brain Tumor Consortium, is a small molecule drug with a specific mechanism of action, currently holding a niche position in the market. The key strength of SSKI lies in its unique mechanism of interaction with a specific target, which differentiates it from other treatments. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | SSKI |
|---|---|
| Also known as | Potassium iodide |
| Sponsor | Pediatric Brain Tumor Consortium |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
Common side effects
- Stomach upset
- Diarrhea
- Nausea
- Vomiting
- Stomach pain
- Skin rash
- Salivary gland swelling or tenderness
- Burning of mouth or throat
- Severe headache
- Metallic taste
- Soreness of teeth and gums
- Symptoms of head cold
Serious adverse events
- Gastrointestinal bleeding
- Angioedema
- Cutaneous and mucosal hemorrhage
- Thyroid adenoma
- Myxedema
- Goiter
- Severe skin eruptions
- Confusion
- Irregular heartbeat
- Serum sickness-like reactions
Key clinical trials
- Cross-Sectional and Longitudinal Studies of "Pre-Diabetes" in the Pima Indians
- Traditional vs. Minimally Invasive Decay Treatments in Primary Molars: An 18-month Split-mouth Randomized Study (NA)
- Preoperative Lugol's Solution in Graves' Disease and Toxic Nodular Goiter (PHASE3)
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma (PHASE2)
- A U.S. Pilot Human Investigation of RadiofrEquency Vapor Ablation System to Evaluate Safety, TOleRability, and Effectiveness for Proximal Intestinal Mucosal Ablation in Patients With Type 2 Diabetes Mellitus (RESTORE-1 Study) (NA)
- MIBG for Refractory Neuroblastoma and Pheochromocytoma (NA)
- Evaluation of a Differentiated Point-of-care Active Case Finding & Management Model to Eliminate Mother-to-Child Transmission of HIV in Malawi (NA)
- Assessment of the Daily Average Requirement of Iodine in Lactating Women (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SSKI CI brief — competitive landscape report
- SSKI updates RSS · CI watch RSS
- Pediatric Brain Tumor Consortium portfolio CI